RT Journal Article
SR Electronic
T1 Population vulnerability to COVID-19 in Europe: a burden of disease analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.29.20064279
DO 10.1101/2020.04.29.20064279
A1 Wyper, Grant MA
A1 Assunção, Ricardo MA
A1 Cuschieri, Sarah
A1 Devleeschauwer, Brecht
A1 Fletcher, Eilidh
A1 Haagsma, Juanita A
A1 Hilderink, Henk
A1 Idavain, Jane
A1 Lesnik, Tina
A1 Lippe, Elena Von der
A1 Majdan, Marek
A1 Milicevic, Milena S
A1 Pallari, Elena
A1 Peñalvo, José L
A1 Pires, Sara M
A1 Plaß, Dietrich
A1 Santos, João V
A1 Stockton, Diane L
A1 Thomsen, Sofie T
A1 Grant, Ian
YR 2020
UL http://medrxiv.org/content/early/2020/05/04/2020.04.29.20064279.abstract
AB Background Evidence has emerged showing that elderly people and those with pre-existing chronic health conditions may be at higher risk of developing severe health consequences from COVID-19. In Europe, this is of particular relevance with ageing populations living with non-communicable diseases, multi-morbidity and frailty. Published estimates of Years Lived with Disability (YLD) from the Global Burden of Disease (GBD) study help to characterise the extent of these effects. Our aim was to identify the countries across Europe that have populations at highest risk from COVID-19 by using estimates of population age structure and YLD for health conditions linked to severe illness from COVID-19.Methods Population and YLD estimates from GBD 2017 were extracted for 45 countries in Europe. YLD was restricted to a list of specific health conditions associated with being at risk of developing severe consequences from COVID-19 based on guidance from the United Kingdom Government. This guidance also identified individuals aged 70 years and above as being at higher risk of developing severe health consequences. Study outcomes were defined as: (i) proportion of population aged 70 years and above; and (ii) rate of YLD for COVID-19 for vulnerable health conditions across all ages. Bivariate groupings were established for each outcome and combined to establish overall population-level vulnerability.Results Countries with the highest proportions of elderly residents were Italy, Greece, Germany, Portugal and Finland. When assessments of population-level YLD rates for COVID-19 vulnerable health conditions were made the highest rates were observed for Bulgaria, Czech Republic, Croatia, Hungary and Bosnia and Herzegovina. A bivariate analysis indicated that the countries at high-risk across both measures of vulnerability were: Bulgaria; Portugal; Latvia; Lithuania; Greece; Germany; Estonia; and Sweden.Conclusion Routine estimates of population structures and non-fatal burden of disease measures can be usefully combined to create composite indicators of vulnerability for rapid assessments, in this case to severe health consequences from COVID-19. Countries with available results for sub-national regions within their country, or national burden of disease studies that also use sub-national levels for burden quantifications, should consider using non-fatal burden of disease estimates to estimate geographical vulnerability to COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. If applicable, open access publications fees upon acceptance of this article in a peer-reviewed journal will be funded under the COST action CA18218 (European Burden of Disease Network).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used in this research study are all publically available. http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2017-permalink/376d9a9ad8401f49f104650fab0b9305